尊龙凯时 - 人生就是搏!

Disclaimer: Products within validity are not offered for sale to the restricted area.
API List（Download PDF）

Therapeutic Area	S/N	API	CAS No.	Remarks
Oncology	1	Pazopanib Hydrochloride	635702-64-6	Technical Package
			（Base：444731-52-6）
	2	Trametinib Dimethyl Sulfoxide	1187431-43-1	Technical Package
			（Base：871700-17-3）
	3	Axitinib	319460-85-0	Technical Package
	4	Dabrafenib Mesylate	1195768-06-9	Technical Package
			（Base：1195765-45-7）
Respiratory	5	Vilanterol Trifenatate	503070-58-4	Technical Package
			（Base：503070-34-8）
	6	Umeclidinium Bromide	869113-09-7	Technical Package
	7	Indacaterol Maleate	753498-25-8	Technical Package
			（Base：312753-06-3）
Anti-Viral	8	Dolutegravir Sodium	1051375-19-9	Technical Package
			（Base：1051375-16-6）
	9	Cabotegravir Sodium	1051375-13-3	In Development
			（Base：1051375-10-0）
Hematologic	10	Eltrombopag Olamine	496775-62-3	Technical Package
			（Base：496775-61-2）
Skeletal musculature	11	Etoricoxib	202409-33-4	In Development
	12	Celecoxib	169590-42-5	USDMF
Ophthalmology	13	Bimatoprost	155206-00-1	In Development
	14	Tafluprost	209860-87-7	In Development
	15	Travoprost	157283-68-6	In Development
	16	Latanoprost	130209-82-4	In Development
APIs	17	Eltrombopag Olamine	496775-62-3	US DMF 38914 NMPA Approval Y20230000603
	18	Trametinib (DMSO)	1187431-43-1	Validation  & Registration in 2025
	19	Dabrafenib  Mesylate	1195768-06-9	Validated WC Available
	20	Ibrutinib (Form A)	936563-96-1	NMPA CDE Y20230001268
	21	Tepotinib Hydrochloride	1100598-32-0	Validated  & registration in 2025
			1946826-82-9
	22	Etrasimod Arginine	1206123-37-6	Under Validation
			1206123-97-8
	23	Fezolinetant	1629229-37-3	Under Validation
	24	Sparsentan	254740-64-2	Pilot
	25	Maralixibat HCl	228113-66-4	Under R&D
	26	Capivasertib	1143532-39-1	Pilot
Excipient	27	Salcaprozate Sodium (SNAC)	203787-91-1	Validation  & Registration in 2025
	28	SM-102	2089251-47-6	R&D
	29	ACL-0315	2036272-55-4	R&D